Indivior PLC (INDV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Indivior PLC (INDV) has a cash flow conversion efficiency ratio of -0.612x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX158.00 Million ≈ $19.22K USD) by net assets (GBX-258.00 Million ≈ $-31.39K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Indivior PLC - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Indivior PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Indivior PLC for a breakdown of total debt and financial obligations.
Indivior PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Indivior PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Smithson Investment Trust PLC
LSE:SSON
|
0.000x |
|
Tuju Setia Bhd
KLSE:5297
|
-0.334x |
|
Higher Way Electronic Co Ltd
TWO:3268
|
-0.040x |
|
Lipidor Ab
ST:LIPI
|
-0.274x |
|
NanoRepro AG
XETRA:NN6
|
0.055x |
|
Naos Ex-50 Opportunities Company Ltd
AU:NAC
|
0.047x |
|
Overactive Media Corp
V:OAM
|
-0.039x |
|
Century Extrusions Limited
NSE:CENTEXT
|
0.095x |
Annual Cash Flow Conversion Efficiency for Indivior PLC (2011–2024)
The table below shows the annual cash flow conversion efficiency of Indivior PLC from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Indivior PLC market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX-348.00 Million ≈ $-42.34K |
GBX36.00 Million ≈ $4.38K |
-0.103x | -100.36% |
| 2023-12-31 | GBX-11.00 Million ≈ $-1.34K |
GBX-315.00 Million ≈ $-38.33K |
28.636x | +36611.36% |
| 2022-12-31 | GBX51.00 Million ≈ $6.21K |
GBX-4.00 Million ≈ $-486.68 |
-0.078x | -104.51% |
| 2021-12-31 | GBX203.00 Million ≈ $24.70K |
GBX353.00 Million ≈ $42.95K |
1.739x | +173.88% |
| 2020-12-31 | GBX82.00 Million ≈ $9.98K |
GBX-193.00 Million ≈ $-23.48K |
-2.354x | -425.77% |
| 2019-12-31 | GBX209.00 Million ≈ $25.43K |
GBX151.00 Million ≈ $18.37K |
0.722x | -84.26% |
| 2018-12-31 | GBX66.00 Million ≈ $8.03K |
GBX303.00 Million ≈ $36.87K |
4.591x | +415.92% |
| 2017-12-31 | GBX-203.00 Million ≈ $-24.70K |
GBX295.00 Million ≈ $35.89K |
-1.453x | -5.33% |
| 2016-12-31 | GBX-295.00 Million ≈ $-35.89K |
GBX407.00 Million ≈ $49.52K |
-1.380x | -20.29% |
| 2015-12-31 | GBX-279.00 Million ≈ $-33.95K |
GBX320.00 Million ≈ $38.93K |
-1.147x | -23.82% |
| 2014-12-31 | GBX-475.00 Million ≈ $-57.79K |
GBX440.00 Million ≈ $53.54K |
-0.926x | +92.27% |
| 2013-12-31 | GBX-66.00 Million ≈ $-8.03K |
GBX791.00 Million ≈ $96.24K |
-11.985x | -300.67% |
| 2012-12-31 | GBX145.00 Million ≈ $17.64K |
GBX866.00 Million ≈ $105.37K |
5.972x | +112.17% |
| 2011-12-31 | GBX254.00 Million ≈ $30.90K |
GBX715.00 Million ≈ $86.99K |
2.815x | -- |
About Indivior PLC
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more